These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38229976)

  • 1. Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report.
    Alshurafa A; Afshan Adil ; Yassin MA
    Case Rep Oncol; 2024; 17(1):96-100. PubMed ID: 38229976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
    Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
    Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
    Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
    Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.
    Choi EJ
    Blood Res; 2023 Apr; 58(S1):S29-S36. PubMed ID: 36891575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
    Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
    García-Gutiérrez V; Hernandez-Boluda JC
    Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
    Monestime S; Al Sagheer T; Tadros M
    Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP.
    Atallah EL; Wei D; Latremouille-Viau D; Rossi C; Damon A; Ferreira G; Guérin A; Jadhav K
    Clin Lymphoma Myeloma Leuk; 2024 Sep; ():. PubMed ID: 39426944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
    Hochhaus A; Réa D; Boquimpani C; Minami Y; Cortes JE; Hughes TP; Apperley JF; Lomaia E; Voloshin S; Turkina A; Kim DW; Abdo A; Fogliatto LM; le Coutre P; Sasaki K; Kim DDH; Saussele S; Annunziata M; Chaudhri N; Chee L; García-Gutiérrez V; Kapoor S; Allepuz A; Quenet S; Bédoucha V; Mauro MJ
    Leukemia; 2023 Mar; 37(3):617-626. PubMed ID: 36717654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
    Hijiya N; Mauro MJ
    Cancer Manag Res; 2023; 15():873-891. PubMed ID: 37641687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
    Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
    Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
    Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
    Pérez-Lamas L; Luna A; Boque C; Xicoy B; Giraldo P; Pérez López R; Ruiz Nuño C; De Las Heras N; Mora Casterá E; López Marín J; Segura Díaz A; Gómez V; Vélez Tenza P; Sierra Pacho M; Vera Goñi JA; Moreno Vega M; Alvarez-Larrán A; Cortés M; Pérez Encinas M; Carrascosa Mastell P; Angona A; Rosell A; Lakhwani S; Colorado M; Ramila E; Cervero C; Cuevas B; Villalón Blanco L; de Paz R; Paz Coll A; Fernández MJ; Felipe Casado L; Alonso-Domínguez JM; Anguita Arance MM; Salamanca Cuenca A; Jiménez-Velasco A; Prendes SO; Santaliestra M; Lis Chulvi MJ; Hernández-Boluda JC; García-Gutiérrez V
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asciminib in chronic myeloid leukemia.
    Assanto GM; Scalzulli E; Breccia M
    Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
    Okabe S; Gotoh A
    BMC Cancer; 2023 Sep; 23(1):827. PubMed ID: 37670241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asciminib for chronic myeloid leukaemia: Next questions.
    Shanmuganathan N; Hughes TP
    Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing
    Gleixner KV; Filik Y; Berger D; Schewzik C; Stefanzl G; Sadovnik I; Degenfeld-Schonburg L; Eisenwort G; Schneeweiss-Gleixner M; Byrgazov K; Sperr WR; Mayer J; Lion T; Valent P
    Am J Cancer Res; 2021; 11(9):4470-4484. PubMed ID: 34659899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.